A Comprehensive Review of PCSK9 Inhibitor Therapy.

Authors

Madelyn Hurwitz, Anandita Kulkarni, Francoise A Marvel, Jaideep Patel

Published in

Journal of cardiovascular pharmacology. Jul 02, 2026. Epub Jul 02, 2026.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a key component of lipid-lowering therapies for atherosclerotic cardiovascular disease risk management in high-risk primary and secondary prevention populations. PCSK9 monoclonal antibodies such as evolocumab and alirocumab were the first agents approved and are the preferred agents given phase 3 trial data supporting improved cardiovascular outcomes. Subgroup analyses of these trials have highlighted high-risk populations that may especially benefit from PCSK9 inhibitor therapy, although demographic disparities persist regarding their implementation. Additional injectable agents with less-frequent dosing schedules have been developed, such as the small-interfering RNA inclisiran, though they lack data regarding cardiovascular outcomes. Oral agents are also in development, with promising data recently presented regarding enlicitide. Additionally, recent trials provide evidence supporting expanded indications for high-risk primary prevention. This review summarizes currently available and investigational PCSK9-targed therapies and examines evidence guiding their clinical implementation.

PMID:
42391098
Bibliographic data and abstract were imported from PubMed on 03 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.